2011 NLA Scientific Sessions Highlights
Clinical Trial Updates Impacting Your PracticeFaculty: Philip J. Barter, MD, PhD
Prof. Barter reviews some recent trials with fibrates, statins, and niacin that he believes should have an impact on current clinical practice.
What Do Simple Genetics Tell Us About Complex Diseases?Faculty: Jonathan C. Cohen, PhD
In the Keynote Presentation of the 7th Annual Scientific Sessions, Dr Cohen reviewed what "simple" genetics can tell us about coronary heart disease (CHD).
The Impact of Prescription Switching on LDL-C Goal AttainmentFaculty: JoAnne M. Foody, MD, FACC, FAHA
Dr Foody focused on the unintended consequences of formulary changes and the potentially harmful effects, with respect to providing evidence-based care or meeting therapeutic goals. She noted that in the United Kingdom (UK), forced switching of high-dose to low-dose statin resulted in higher rates of death, cardiac death, and non-cardiac death in individuals switched to the lower dose.
Common Etiologies of HypertriglyceridemiaFaculty: Henry N. Ginsberg, MD
At least 95% of people with type-2 diabetes are insulin resistant. In the adipose tissue, insulin-resistant cells release fatty acids, increasing fatty acid flux to the liver resulting in transformation of the excess into triglycerides (TG)
Genetic Susceptibility to Statin-Induced MyopathyFaculty: Georgirene D. Vladutiu, PhD
Severe statin myopathy is usually defined as severe muscle damage with damage to another organ, such as a kidney, and creatinine kinase (CK) ≥10 x upper limit of normal (ULN). However, some severely affected patients have serum CK <10 x ULN. Of 166 patients with severe statin myopathy referred to Dr Vladutiu's laboratory, 40% had CK ≥10 x ULN, 30% had CK 4-9 x ULN, and 10-15% had CK 2-3 x ULN.
Novel Therapies on the HorizonFaculty: M. John Chapman, PhD, DSc, FESC
According to Dr. Chapman, there are a number of therapeutic agents on the horizon that normalize levels of Apolipoprotein A-I (ApoA-I) and high-density lipoprotein cholesterol (HDL-C) for the acute and/or chronic treatment of patients at high cardiometabolic risk.
The Case For A Low-Fat/Good Carbohydrate DietFaculty: Eric C. Westman, MD, MHS
In his presentation, Dr Westman sought to dispel some "myths" and answer criticisms about the low-carbohydrate (low-carb) diet. He maintains that someone in a wheelchair can lose weight, even if they do not exercise, just by changing their diet.
The Case For A Low-Fat/Good Carbohydrate DietFaculty: John P. Foreyt, PhD
All major dietary guidelines, including those of the Institute of Medicine (IOM), the American Dietetic Association (ADA), and National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), all recommend 25-30% calories come from fat, i.e., a low-fat diet.
CKD in the Light of The SHARP TrialFaculty: George L. Bakris, MD, FAHA, FASN
Individuals with chronic kidney disease (CKD) have raised levels of triglycerides and decreased levels of high-density lipoprotein cholesterol (HDL-C), as well as elevations in low-density lipoprotein cholesterol (LDL-C).
HDL Functionality: How Do We Measure It and Is It Relevant to Everyday Clinical Practice?Faculty: Daniel J. Rader, MD, FNLA
It is not universally acknowledged that the relationship between high-density lipoprotein cholesterol (HDL-C) and coronary heart disease (CHD) risk is truly causal, and that targeting HDL-C levels automatically reduces risk.